Managing dry eye
The area of dry eye treatment has exploded, from Dr. Gulani’s perspective.
The recently acquired TearScience (Johnson & Johnson Vision) and a number of companies in the dry eye arena have made dry eye management their mission.
“If we can apply technology, technique, and pharmaceuticals in a logical fashion, there is more than just hope for patients with dry eye,” he said. “Clinicians are very well equipped today to understand and treat dry eye.”
In addition to measuring osmolarity and tear film analysis, Dr. Gulani uses the Ocular Keratograph (Oculus) to obtain an extensive evaluation of the quality and stability of the tear film along with a patient-friendly Jenvis report (Oculus).
Another addition to the market this year is lifitegrast (Xiidra, Shire), the first new pharmaceutical for dry eye in more than a decade.